Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery

The Lancet Oncology

Volumn 14, Issue 9, 2013, Pages

  Benson, John R ^a,b   Wishart, Gordon C ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN P16; PROTEIN P53; TAMOXIFEN;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; FAMILY HISTORY; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LOW RISK POPULATION; PARTIAL MASTECTOMY; POSTMENOPAUSE; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; RADIATION INJURY; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; TUMOR INVASION; TUMOR VOLUME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84880814807     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70135-9     Document Type: Review

References (73)

1. American Cancer Society breast cancer facts and figures American Cancer Society, (accessed Feb 10, 2013). http://www.cancer.org/Research/CancerFactsFugures/BreastCancerFactsFugures/breast-cancer-facts-and-figures-2011-2012.
2. Tabar L, Smith RA, Vitak B, et al. Mammographic screening: a key factor in the control of breast cancer. Cancer J 2003, 9:15-27.
3. Silverstein MJ, Lagios MD, Recht A, et al. Image-detected breast cancer: state of the art diagnosis and treatment. J Am Coll Surg 2005, 201:586-597.
4. The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786. Independent UK Panel on Breast Cancer Screening.
5. Rosen PP, Braun DW, Kinne DE The clinical significance of pre-invasive breast cancer. Cancer 1980, 46:919-925.
6. Nielsen M, Jensen J, Andersen J Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women. Cancer 1984, 54:612-615.
7. Bartow SA, Pathak DR, Black WC, et al. Prevalence of benign, atypical and malignant breast lesions in populations at different risk for breast cancer: a forensic autopsy study. Cancer 1987, 60:2751-2760.
8. Anderson TJ Genesis and source of breast cancer. Br Med Bull 1991, 47:305-318.
9. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998, 16:1367-1373.
10. Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg 2004, 188:371-376.
11. Gotzsche PC, Olsen O Is screening for breast cancer with mammography justifiable?. Lancet 2000, 355:129-134.
12. Wapnir I, Dignam JJ, Fisher B, et al. Long term outcomes of invasive ipsilateral breast tumour recurrences after lumpectomy in NSABP B-17 and B-24 randomised clinical trials for DCIS. J Natl Cancer Inst 2011, 103:478-488.
13. Bijker N, Meijnen P, Peterse JL, et al. Breast conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomised Phase III Trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006, 24:1-8.
14. Cuzik J, Sestak I, Pinder S, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long term results from the UK/ANZ DCIS trial. Lancet Oncol 2011, 12:21-29.
15. Seth A, Kitching R, Landberg G, et al. Gene expression profiling of ductal carcinomas in situ and invasive breast tumours. Anticancer Res 2003, 23:2043-2051.
16. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003, 100:5974-5979.
17. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004, 350:1430-1441.
18. Baxter N, Virnig BA, Durham SB, et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004, 96:443-448.
19. Schnitt SJ Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Am J Clin Pathol 2003, 120:485-488.
20. Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994, 74:1746-1751.
21. Kell MR, Morrow M An adequate margin of excision in ductal carcinoma in situ. BMJ 2005, 331:789-790.
22. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
23. Allred DC, Bryant L, Land S, et al. Estrogen receptor expression as a predictive marker of effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP Protocol B-24. Breast Cancer Res Treat 2003, 76:36.
24. Smitt MC, Nowels K, Carlson RW, et al. Predictors of re-excision findings and recurrence after breast conservation. Int J Radiat Oncol Biol Phys 2003, 57:979-985.
25. Singletary SE Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002, 184:383-393.
26. Wapnir I, Anderson S, Mamounas E, et al. Survival after IBTR in NSABP node negative protocols B-13, B-14, B-19, B-20 and B-23. J Clin Oncol 2005, 23:517.
27. Kaufmann M, Morrow M, von Minckwitz G, et al. Locoregional treatment of primary breast cancer: consensus recommendations from an International Expert Panel. Cancer 2010, 116:1184-1191.
28. Faverley DR, Burgers L, Bult P, Holland R Three-dimensional imaging of mammary ductal carcinoma in situ: clinical implications. Semin Diagn Pathol 1994, 11:193-198.
29. Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999, 340:1455-1461.
30. Dunne C, Burke JP, Morrow M, Kell MR Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009, 27:1615-1620.
31. NICE. Breast cancer (early & locally advanced): diagnosis and treatment. NICE Clinical Guideline 2009; 80.
32. Toi M, Winer EP, Inamoto T, et al. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol 2011, 18:2885-2892.
33. Wang S-Y, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for women with ductal carcinoma in situ. J Natl Cancer Inst 2012, 104:507-516.
34. Vicini F, Kestin LL, Goldstein NS, et al. Relationship between excision volume, margin status and tumor size with the development of local recurrence in patients with carcinoma in situ treated with breast conserving surgery. J Surg Oncol 2001, 76:245-254.
35. Down SK, Burger A, Hussein M Oncological advantages of oncoplastic breast conserving surgery in treatment of early breast cancer. Breast J 2013, 19:5-63.
36. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106. Early Breast Cancer Trialists' Collaborative Group.
37. Hughes L, Wang M, Page D, et al. Local excision alone without radiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27:5319-5324.
38. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006, 24:1031-1036.
39. Holland R, Peterse JL, Millis R, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11:167-180.
40. Lagios MD, Margolin FR, Westdahl PR, et al. Mammographically detected ductal carcinoma in situ: frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63:618-624.
41. Silverstein MJ, Barth A, Poller DN, et al. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 1995, 9:1425-1427.
42. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996, 14:754-763.
43. Wang S-Y, Shamliyan T, Virnig BA, Kane R Tumour characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011, 127:1-14.
44. Habel LA, Daling JR, Newcomb PA, et al. Risk of recurrence after ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 1998, 7:689-696.
45. Solin L, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast conserving surgery and definitive irradiation: correlation of pathologic parameters with outcome of treatment. Cancer 1993, 71:2532-2542.
46. Silverstein MJ, Lagios MD Ductal carcinoma in situ of the breast. Early breast cancer: from screening to multidisciplinary management 2013, 341-360. CRC Press Taylor and Francis Group, Boca Raton, FL. J.R. Benson, T. Tuttle, G. Gui (Eds.).
47. Silverstein MJ, Poller D, Craig P, et al. Predicting local recurrence in patients with intraductal breast carcinoma (DCIS). Proc Am Soc Clin Oncol 1995, 14:117.
48. Silverstein MJ The University of Southern California/Van Nuys Prognostic Index for ductal carcinoma in situ of the breast. Am J Surg 2003, 186:337-343.
49. McCormick B, Rosen PP, Kinne D, et al. Ductal carcinoma in situ of the breast: an analysis of local control after conservation surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1991, 21:289-292.
50. Hiramatsu H, Bornstein BA, Recht A, et al. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: possible importance of family history. Cancer J Sci Am 1995, 1:55-61.
51. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor and HER2 is associated with local and distant recurrence after breast conserving therapy. J Clin Oncol 2008, 26:2373-2378.
52. Farabegoli F, Champeme MH, Bieche I, et al. Genetic pathways in the evolution of breast ductal carcinoma in situ. J Pathol 2002, 196:280-286.
53. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma in situ (DCIS) versus invasive breast cancer alone. Anticancer Res 2005, 25:1719-1723.
54. Park K, Han S, Kim HJ, Kim J, Shin E HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 2006, 48:702-707.
55. Steinman S, Wang J, Bourne P, Yang Q, Tang P Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 2007, 37:127-134.
56. Schuetz CS, Bonin M, Clare SE, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006, 66:5278-5286.
57. Castro NP, Osorio CABT, Torres C, et al. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res 2008, 10:R87.
58. Gauthier ML, Berman HK, Miller C, et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumours. Cancer Cell 2007, 12:479-491.
59. Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010, 102:627-637.
60. Joh JE, Esposito NN, Kiluk JV, et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 2011, 16:1520-1526.
61. Solin L, Gray R, Baehner F, et al. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS Score from ECOG E5194. 34th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 6-10, 2011. S4-6 (abstr).
62. Sakr RA, Chandarlapaty S, Giovanni C et al. Molecular predictors for type of recurrence following conservative treatment for DCIS. 35th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 4-8, 2012. PD04-05 (abstr).
63. Williams KE, Barnes NLP, Cheema K, Dimipoulos N, Landberg G, Bundred NJ. Molecular phenotypes of DCIS predict invasive and DCIS recurrence. 35th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 4-8, 2012. PD04-06 (abstr).
64. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010, 41:162-177. Early Breast Cancer Trialists Collaborative Group.
65. Viani GA, Stefano EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol 2007, 2:28-39.
66. Goodwin A, Parker S, Ghersi D, et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2009, 4. CD000563.
67. Carlson RW, Berry DA, Burstein HJ, et al. NCCN clinical practice guidelines in oncology: breast cancer (accessed June 19, 2013). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
68. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP Protocol B-24. J Clin Oncol 2012, 30:1268-1273.
69. Cuzick J IBIS II: a breast cancer prevention trial in post-menopausal women using the aromatase inhibitoranastrozole. Expert Rev Anticancer Ther 2008, 8:1377-1385.
70. Schwartz G Treatment of subclinical ductal carcinoma in situ of the breast by local excision and surveillance: an updated personal experience. Ductal carcinoma in situ of the breast 2002, 308-321. Lippincott Williams & Wilkins, Philadelphia, PA. M.J. Silverstein, A. Recht, M. Lagios (Eds.).
71. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast conserving surgery for ductal carcinoma in situ. J Clin Oncol 2010, 30:5319-5324.
72. Olivoto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005, 12:2716-2725.
73. Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012, 107:800-807.